Affiliation:
1. Institute of Pharmaceutical Research, GLA University, Mathura-281406, Uttar Pradesh, India
Abstract
Abstract:
Cardiovascular disorders (CVDs) are the leading cause of death worldwide and are
accelerated via the low level of low-density lipoprotein-cholesterol (LDL-C). The proprotein
convertase subtilis/kexin type9 (PCSK9), a vital regulator and a biomarker, circulates for the
LDL-C and has the degradation capability of the low-density lipoprotein receptor (LDLR).
PCSK9 has modulated the overall mechanism by transcription, secretion, clearance, or extracellular
inactivation in the past few years.PCSK9 has specific pathophysiological roles in many cardiovascular
cells. The initial data on the PCSK9 inhibitor, Evolocumab, has a specific reduction
in the composite end-point, such as cardiovascular, myocardial, and stroke, while the rest of the
data release is still under wait. Furthermore, it is witnessed that the U.S. and the European authorities
have approved two humanized antibodies against the LDL-R binding site of PCSK9.
This review highlighted the recent data findings on the PCSK9 and its regulation, focusing on
cardiovascular disorders, and summarized the current clinical studies. Thus it provides a ray of
hope to overcome statin intolerance and alternative approaches for PSCK9 inhibition and significantly
reduce cardiovascular complications. This review plays a pivotal role for the researchers
and scientists working on PCSK9 inhibitors to treat cardiovascular disorders.
Publisher
Bentham Science Publishers Ltd.
Subject
General Health Professions